GDMC

About GDMC

Genetic Design and Manufacturing Corporation (GDMC) was a Singapore-based biotechnology firm established in 2021 by CEO and Co-Founder Michael Koeris, an entrepreneur with over two decades of experience in the biotech and healthcare sectors. The company aimed to address key bottlenecks in the genetic medicines field by providing integrated services for product design, development, and manufacturing.

GDMC operated as a Partnership for Drug Manufacturing Organization (PDMO), a model designed to offer comprehensive support to other companies, including startups, from the initial drug design phase through to quality assurance and regulatory support for market entry. This approach focused on fostering success-based partnerships with its clients, emphasizing technical collaboration and reducing the cost of goods. The company's business model centered on generating revenue through manufacturing services for advanced therapies and forming strategic partnerships that aligned its financial success with that of its clients' products as they progressed through clinical trials. GDMC's target clients were primarily early-stage biotechs and research investigators in the United States and the Asia-Pacific region who are developing genetic medicines.

The firm specialized in the design and manufacturing of high-value genetic medicines, including mRNA vaccines and therapies, as well as cell and gene therapies. Its specific offerings included customized plasmid DNA, Viral Vectors (such as AAV and Lentiviral), and mRNA. A core component of GDMC's strategy was its 'design by synthetic biology' approach, which involved working closely with drug developers from the outset to optimize manufacturing processes and reduce development time. In January 2024, GDMC announced it had secured $21 million in a Series A funding round led by Celadon Partners, with participation from investors like WI Harper Group, SEEDS Capital, and NSG Ventures. These funds were intended to expand its operations and advance the construction of a 155,000-square-foot facility in Singapore to support preclinical, clinical, and commercial manufacturing. However, in June 2024, the company filed for liquidation.